21.09.2011 • NewsSanofi PasteurSanofiVaccines

Sanofi Pasteur Acquires Worldwide License For Acne Vaccine, Treatment

Sanofi Pasteur, the vaccines division of Sanofi-Aventis, announced a research and development collaboration with the University of California, San Diego on an immunological approach to acne prevention and treatment targeting the specific neutralization of Propionibacterium acnes factors in inflammation. The financial terms of the agreement were not disclosed.

The agreement includes a two-year research collaboration with Dr. Chun-Ming Huang and his associates at UC San Diego School of Medicine for further research and development.

According to Sanofi Pasteur's estimates, the annual worldwide market for acne therapeutics is in excess of $3 billion.

Elias Zerhouni, president, Global Research & Development, Sanofi, said, "This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need. This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.